Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed. Materials and Methods Patients with curatively resected stage IB-IIB pancreatic adenocarcinoma were eligible. Treatment consisted of chemotherapy with gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 every 3 weeks for two cycles, followed by chemoradiotherapy (50.4 Gy/28 fx) with weekly gemcitabine (300 mg/m2/wk), and then gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks for four cycles. The primary endpoint was 1-year disease-free survival rate. The secondary endpoints were disease-free survival, overall survival, and safety. Results Seventy-four patients were enrolled. One-year disease-free survival rate was 57.9%. Median disease-free and overall survival were 15.0 months (95% confidence interval [CI], 11.6 to 18.4) and 33.0 months (95% CI, 21.8 to 44.2), respectively. At the median follow-up of 32 months, 57 patients (77.0%) had recurrence including 11 patients whose recurrence was during the adjuvant treatment. Most of the recurrences were systemic (52 patients). Stage at the time of diagnosis (70.0% in IIA, 51.2% in IIB, p=0.006) were significantly related with 1-year disease-free survival rate. Toxicities were generally tolerable, with 53 events of grade 3 or 4 hematologic toxicity and four patients with febrile neutropenia. Conclusion Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine and maintenance gemcitabine showed efficacy and good tolerability in curatively resected pancreatic cancer.
Abstract
Purpose Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed. Materials and Methods Patients with curatively resected stage IB-IIB pancreatic adenocarcinoma were eligible. Treatment consisted of chemotherapy with gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 every 3 weeks for two cycles, followed by chemoradiotherapy (50.4 Gy/28 fx) with weekly gemcitabine (300 mg/m2/wk), and then gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks for four cycles. The primary endpoint was 1-year disease-free survival rate. The secondary endpoints were disease-free survival, overall survival, and safety. Results Seventy-four patients were enrolled. One-year disease-free survival rate was 57.9%. Median disease-free and overall survival were 15.0 months (95% confidence interval [CI], 11.6 to 18.4) and 33.0 months (95% CI, 21.8 to 44.2), respectively. At the median follow-up of 32 months, 57 patients (77.0%) had recurrence including 11 patients whose recurrence was during the adjuvant treatment. Most of the recurrences were systemic (52 patients). Stage at the time of diagnosis (70.0% in IIA, 51.2% in IIB, p=0.006) were significantly related with 1-year disease-free survival rate. Toxicities were generally tolerable, with 53 events of grade 3 or 4 hematologic toxicity and four patients with febrile neutropenia. Conclusion Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine and maintenance gemcitabine showed efficacy and good tolerability in curatively resected pancreatic cancer.
참고문헌 (30)
- Saif MW, "Controversies in the adjuvant treatment of pancreatic adenocarcinoma", JOP, 8, pp.545~552 (2007)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- Kalser MH, "Pancreatic cancer : adjuvant combined radiation and chemotherapy following curative resection", Arch Surg, 120, pp.899~903 (1985)
- Regine WF, "Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma : a randomized controlled trial", JAMA, 299, pp.1019~1026 (2008)
- Neoptolemos JP, "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer", N Engl J Med, 350, pp.1200~1210 (2004)
- Katz MH, "Current status of adjuvant therapy for pancreatic cancer", Oncologist, 15, pp.1205~1213 (2010)
- Neoptolemos JP, "Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer(ESPAC-4) : a multicentre, openlabel, randomised, phase 3 trial", Lancet, 389, pp.1011~1024 (2017)
- Uesaka K, "Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, openlabel, randomised, non-inferiority trial(JASPAC 01)", Lancet, 388, pp.248~257 (2016)
- Klinkenbijl JH, "Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region : phase III trial of the EORTC gastrointestinal tract cancer cooperative group", Ann Surg, 230, pp.776~782 (1999)
- Oettle H, "Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial", JAMA, 297, pp.267~277 (2007)
- Corsini MM, "Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma : the Mayo Clinic experience(1975-2005)", J Clin Oncol, 26, pp.3511~3516 (2008)
- Herman JM, "Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas : results of a large, prospectively collected database at the Johns Hopkins Hospital", J Clin Oncol, 26, pp.3503~3510 (2008)
- Conroy T, "FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer", N Engl J Med, 379, pp.2395~2406 (2018)
- Tempero MA, "APACT : phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine(nab-P", G)vs gemcitabine(G)for surgically resected pancreatic adenocarcinoma, 2019, pp.37(15Suppl), 4000~
- Liao WC, "Adjuvant treatments for resected pancreatic adenocarcinoma : a systematic review and network meta-analysis", Lancet Oncol, 14, pp.1095~1103 (2013)
- "Pancreatic adenocarcinoma, version 1.2020" (2020)[URL]
- Khorana AA, "Potentially curable pancreatic cancer : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 34, pp.2541~2556 (2016)
- Peters GJ, "Preclinical combination therapy with gemcitabine and mechanisms of resistance", Semin Oncol, 23(5 Suppl 10), pp.16~24 (1996)
- Philip PA, "Gemcitabine and platinum combinations in pancreatic cancer", Cancer, 95(4 Suppl), pp.908~911 (2002)
- Blackstock AW, "Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer", J Clin Oncol, 17, pp.2208~2212 (1999)
- Van Laethem JL, "Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma : a phase II study", Int J Radiat Oncol Biol Phys, 56, pp.974~980 (2003)
- Crane CH, "Combining gemcitabine with radiation in pancreatic cancer : understanding important variables influencing the therapeutic index", Semin Oncol, 28(3 Suppl 10), pp.25~33 (2001)
- McGinn CJ, "On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer", Cancer, 95(4 Suppl), pp.933~940 (2002)
- Colucci G, "Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and", or metastatic pancreatic carcinoma : a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale, 2002, pp.94, 902~910
- Heinemann V, "Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer", J Clin Oncol, 24, pp.3946~3952 (2006)
- Ducreux M, "A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma", Ann Oncol, 13, pp.1185~1191 (2002)
- Further evidence of effective adjuvant combined radiation, "Gastrointestinal Tumor Study Group", Cancer, 59, pp.2006~2010 (1987)
- Neoptolemos JP, "Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial", JAMA, 304, pp.1073~1081 (2010)
- Nie RC, "Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer : a meta-analysis of 20 randomized controlled trials", BMC Cancer, 20, pp.421~ (2020)
- Bilimoria KY, "Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database", Cancer, 110, pp.738~744 (2007)